Capital

DENOSUMAB: PROLIA®; JUBBONTI ®; XGEVA®; WYOST®
PREAUTHORIZATION REQUEST
(PREAUTHORIZATION IS NOT A GUARANTEE OF PAYMENT)

SECTION I – General information	
Today's date: / /	☐ New request
Fax completed form to: **866.805.4150 toll free.**	☐ Re-authorization

Level of urgency:

Standard request (routine care) - care/treatment that is not emergent, urgent, or preventive in nature.

Expedited request - care/treatment that is emergent or the application of the timeframe for making standard/routine or nonlife-threatening care determinations:

- Could seriously jeopardize the life, health, or safety of the member or others, due to the member's psychological state.
- In the opinion of the practitioner with knowledge of the member's medical or behavioral condition, would subject the member to adverse health consequences without the care or treatment that is the subject of the request.

For expedited request, please explain:

SECTION II – Member information		
Patients name:	Member ID:	**Patient information**: DOB: __/__/__ Sex: Age: Weight: ☐ lbs. ☐ kg Will the patient self-administer the requested medication? ☐ Yes ☐ No
Patients address:	Is Capital Blue Cross primary payer: ☐ Yes ☐ No	

Capital

Plan type:

☐ PPO ☐ POS ☐ KHPC ☐ CHIP

☐ Traditional ☐ Comprehensive ☐ Special Care ☐ Other* _____

NOTE: For all Medicare Advantage products, please contact Prime Therapeutics at www.covermymeds.com/main or via phone at 866.260.0452.

SECTION III – Provider information required	
Requesting provider name: **Address**:	**Requesting provider Capital #**_____ **NPI #** _____
Telephone #:	Secure fax #:
Office contact name:	Office contact telephone #:
Is the rendering/servicing provider different? ☐ No ☐ Yes – Complete rendering provider information below.	
Rendering provider name: **Address**: **Telephone:**	**Rendering provider Capital #**_____ **NPI #** _____
Site of service: ☐ MD office. ☐ Home health. ☐ Non-hospital affiliated, outpatient infusion center. ☐ Hospital affiliated, outpatient infusion center. ☐ Other: Specify. _____ **Please refer to MP 3.016 for site of service requirements.*	**Check all that apply and include all applicable documentation:** ☐ There are contraindications to a less intensive site of care. ☐ A less intensive site of care is not appropriate for the patient's condition. ☐ Patient is being treated with a drug that cannot be administered in a less intensive site of care concurrently. ☐ Less intensive site of care is not available. **Please include all applicable documentation.*

Capital

SECTION IV – Preauthorization requirements and clinical criteria

Is the prescriber a specialist in the area of the patient's diagnosis or has the prescriber consulted with a specialist in the area of the patient's diagnosis? ☐ Yes Specialty: _____ ☐ No

☐ New to therapy. ☐ Continuing therapy*: Initial start __/__/__. ☐ Reinitiating therapy: Last treatment __/__/__. *Please include documentation for changes in dose.	**Route of administration:** ☐ Intravenous (IV). ☐ Injection (Sub Q or IM). ☐ Oral (PO) or Enteral. ☐ Other: Specify. _____
HCPCS code(s):	**Diagnosis code(s)**:
Medication requested:	**Indication:**

Does the patient have late-stage metastatic disease? ☐ Yes ☐ No

For patients with late-stage metastatic disease (Stage IV), please refer to MP 2.373 Step Therapy Treatment in Cancer, Including Treatments for Stage Four, Advanced Metastatic Cancer and Severe Related Health Conditions for additional guidance.

Type of drug requested: ☐ Brand name ☐ Generic ☐ Biosimilar ☐ Other: Specify _____

Initial start date of therapy: __/__/__	Anticipated date of **next administration:** __/__/__

Dosing period for request: Start date: __/__/__ End date: __/__/__	**Dosing Information:** Dose: Strength: Frequency: Quantity requested per month:

Attach documentation demonstrating the medical necessity of the requested drug. Please list all reasons for selecting the requested medication, strength, dosing schedule, and quantity over alternatives (e.g., contraindications, allergies, history of adverse drug reactions to alternatives, lower dose has been tried, information supporting dose over FDA max.)

Has the patient had **medical testing** completed for use of this drug? (labs, imaging) ☐ Yes ☐ No

Results: _____

Is drug being requested for an "**off label" indication**? ☐ Yes ☐ No

If yes, please see Medical Policy 2.103 and include any applicable documentation.

Please list any previous medications that were **tried and failed**. Include reason for discontinuation (intolerance, hypersensitivity, inadequate response etc.). Please attach documentation.

Drug(s) and strength:

Documentation of failure:

Capital

Check drug being prescribed and please answer the universal criteria questions.

☐ **Prolia** ☐ **Jubbonti**

- Is the patient at least 18 years of age? □ Yes □ No
- Is the patient supplementing with 1,000mg of calcium and at least 400IU of vitamin D daily? □ Yes □ No
- Does the patient have hypocalcemia? □ Yes □ No
- Does the patient have advanced kidney disease and will be monitored for the presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) with intact parathyroid horone(iPTH), serum calcium, 25(OH) vitamin D, and 1,25 $(OH)_2$ vitamin D prior to decisions regarding denosumab treatment? □ Yes □ No
- Is the patient a biologic female of child-bearing potential, and pregnancy has been ruled out? □ Yes □ No
- Will patient use in combination with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/ related peptides? □ Yes □ No

☐ **Xgeva** ☐ **Wyost**

- Will patient be taking calcium and vitamin D as necessary to treat or prevent hypocalcemia? □ Yes □ No
- Does the patient have hypocalcemia? □ Yes □ No
- Will patient use in combination with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/ related peptides? □ Yes □ No

Capital

COMPLETE BELOW FOR RELEVANT INDICATION

Prolia & Jubbonti

□ **Osteoporosis in men and women**

- Is the patient a biologic female and post-menopausal? □ Yes □ No
- Is the patient at a high risk for fracture? □ Yes □ No
- Does the patient have a documented diagnosis of osteoporosis indicated by one or more of the following:
- T-score by DXA of ≤-2.5 measured at the lumbar spine, femoral neck, total hip, or forearm at the 33% (one-third) radius site. □ Yes □ No
- History of fragility fracture to the hip or spine, regardless of T-score. □ Yes □ No
- T-score by DXA between -1.0 and -2.5 measured at the lumbar spine, femoral neck, total hip, or forearm at the 33% (one-third) radius site. □ Yes □ No
    - History of fracture of proximal humerus, pelvis, or distal forearm; or FRAX 10-year probability for major fracture ≥ 20% or hip fracture ≥ 3%.□ Yes □ No
- Is there documented treatment failure or ineffective response* to a minimum (12) month trial on previous therapy with bisphosphonates (oral or IV) such as alendronate, risedronate, ibandronate, or zoledronic acid? □ Yes □ No
- Does the patient have a documented contraindication** or intolerance to BOTH oral bisphosphonates and intravenous (IV) bisphosphonates such as alendronate, risedronate, ibandronate, or zoledronic acid? □ Yes □ No

□ **Glucocorticoid-induced osteoporosis**

- Patient will be initiating or is continuing systemic glucocorticoid therapy at a daily dosage equivalent to ≥ 2.5mg of prednisone and is expected to remain on glucocorticoid therapy for at least 3 months? □ Yes □ No
- Patient is at an increased risk of fracture with one of the following:
- Documented treatment failure or ineffective response* to a minimum (12) month trial on previous therapy with bisphosphonates (oral or IV) such as alendronate, resedronate, ibandronate, or zoledronic acid? □ Yes □ No
- Documented contraindication or intolerance to BOTH oral bisphosphonates and intravenous (IV) bisphosphonates such as alendronate, risedronate, ibandronate, or zoledronic acid? □ Yes □ No

□ **Osteoporosis treatment and prevention in prostate cancer patients**

- Is the patient receiving androgen deprivation therapy? □ Yes □ No
- Is the patient at a high risk for fracture? □ Yes □ No

□ **Osteoporosis treatment and prevention in breast cancer patients**

- Is the patient receiving adjuvant aromatase inhibitor therapy for breast cancer? □ Yes □ No

*Ineffective response is defined as one or more of the following: decrease in T-score in comparison with baseline T-score from DXA scan and/or patient has a new fracture while on bisphosphonate therapy.

Xgeva & Wyost

□ **Prevention of skeletal-related events in patients with multiple myeloma or bone metastases from solid tumors**

- Is the patient at least 18 years of age? □ Yes □ No
- Has the patient tried and had an inadequate response, contraindication, or intolerance to at least a three (3) month trial of zoledronic acid? □ Yes □ No
- Does the patient have metastatic breast cancer, metastatic castration-resistant prostate cancer, or metastatic lung cancer (both SCLC and NSCLC)? □ Yes □ No

□ **Giant cell tumor of the bone**

- Is the patient an adult or at least 12 years of age and skeletally mature? □ Yes □ No
- Is the disease unresectable or surgical resection likely to result in severe morbidity? □ Yes □ No
- Is the disease localized, recurrent, or metastatic? □ Yes □ No
- If yes to the above question, will the drug be used as a single agent or used in combination with interferon alpha, serial embolization and/or radiation therapy? □ Yes □ No

□ **Hypercalcemia of malignancy**

- Is the patient at least 18 years of age with a diagnosis of cancer (malignancy)? □ Yes □ No
- Does the patient have a diagnosis of refractory hypercalcemia of malignancy defined as an albumin-corrected calcium of > 12.5 mg/dL (3.1 mmol/L) despite treatment with a minimum seven (7) day trial on previous therapy with intravenous (IV) bisphosphonates such as ibandronate or zoledronic acid? □ Yes □ No
- Does the patient have a documented contraindication or intolerance to intravenous (IV) bisphosphonates such as ibandronate or zoledronic acid? □ Yes □ No

□ **Systemic mastocytosis**

- Does the patient have osteopenia or osteoporosis and coexisting bone pain? □ Yes □ No
- Is this drug being used as second line therapy and patient is not responding to bisphosphonate therapy? □ Yes □ No
- Is the patient not a candidate for bisphosphonate therapy due to renal insufficiency? □ Yes □ No

RENEWAL CRITERIA (You will also need to complete the indication section above to show that patient continues to meet indication-specific relevant criteria)

Has the patient experienced unacceptable toxicity* from the drug? □ Yes □ No

**Examples of unacceptable toxicity include the following: severe symptomatic hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, dermatological adverse reactions, severe infection, severe hypersensitivity/anaphylaxis, musculoskeletal pain, etc.*

Prolia & Jubbonti

Has the patient shown beneficial disease response as indicated by absence of fractures and/or increase in bone mineral density compared to pretreatment baseline? □ Yes □ No

□ **Osteoporosis in men and women**

- After 5 years of treatment, will the patient have a repeat DXA performed? □ Yes □ No
- If the patient has low to moderate risk disease, will his/her therapy be changed to an oral or IV bisphosphonate unless there is a contraindication or intolerance to both dosage forms? □ Yes □ No

□ **Glucocorticoid-induced osteoporosis**

- After 2 years of treatment, will the patient have a repeat DXA performed? □ Yes □ No
- If the patient has low to moderate risk disease, will his/her therapy be changed to an oral or IV bisphosphonate unless there is a contraindication or intolerance to both dosage forms? □ Yes □ No

Xgeva & Wyost

Patient has beneficial disease response indicated by one of the following:

□ **Multiple myeloma or bone metastases from solid tumors**

- Has the patient experienced an absence/delay in skeletal-related events (e.g., pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression)? □ Yes □ No

□ **Giant cell tumor of the bone**

- Has the patient experienced stabilization of disease or decrease in size of tumor or spread of tumor? □ Yes □ No

□ **Hypercalcemia of malignancy**

- Does the patient have a corrected serum calcium ≤ 11.5 mg/dL (2.9 mmol/L)? □ Yes □ No

□ **Systemic mastocytosis**

- Has the patient experienced improvement or resolution of bone pain as compared to pretreatment baseline? □ Yes □ No

Capital

Please use a separate form for each drug. To fill out form type or write using blue or black ink. **Please fax this form to: 866.805.4150.** Telephone: 800.471.2242.	**CONFIDENTIALITY NOTICE**: This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 800.471.2242. Thank you for your cooperation.
Prior authorization is not a guarantee of payment; benefits and eligibility will apply at the time of claim adjudication.	

Healthcare benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the Blue Cross Blue Shield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.